ANI Pharmaceuticals (NASDAQ:ANIP) Vs. SAGE, RCUS, IMAB, AUPH, TGTX, OPK, EQRX, NKTR, CORT, and HRMY
Should you be buying ANI Pharmaceuticals stock or one of its competitors? The main competitors of ANI Pharmaceuticals include Sage Therapeutics (SAGE), Arcus Biosciences (RCUS), I-Mab (IMAB), Aurinia Pharmaceuticals (AUPH), TG Therapeutics (TGTX), OPKO Health (OPK), EQRx (EQRX), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical preparations" industry.
ANI Pharmaceuticals vs.
ANI Pharmaceuticals (NASDAQ:ANIP) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, community ranking, valuation, profitability, dividends and risk.
ANI Pharmaceuticals received 245 more outperform votes than Arcus Biosciences when rated by MarketBeat users. Likewise, 66.29% of users gave ANI Pharmaceuticals an outperform vote while only 66.12% of users gave Arcus Biosciences an outperform vote.
ANI Pharmaceuticals has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500.
ANI Pharmaceuticals has higher revenue and earnings than Arcus Biosciences. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.
ANI Pharmaceuticals has a net margin of -10.40% compared to Arcus Biosciences' net margin of -735.12%. ANI Pharmaceuticals' return on equity of 17.80% beat Arcus Biosciences' return on equity.
ANI Pharmaceuticals presently has a consensus price target of $67.50, suggesting a potential upside of 63.64%. Arcus Biosciences has a consensus price target of $62.33, suggesting a potential upside of 101.53%. Given Arcus Biosciences' higher probable upside, analysts clearly believe Arcus Biosciences is more favorable than ANI Pharmaceuticals.
In the previous week, ANI Pharmaceuticals had 2 more articles in the media than Arcus Biosciences. MarketBeat recorded 6 mentions for ANI Pharmaceuticals and 4 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of -0.01 beat ANI Pharmaceuticals' score of -0.05 indicating that Arcus Biosciences is being referred to more favorably in the news media.
51.3% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 62.9% of Arcus Biosciences shares are owned by institutional investors. 23.5% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 12.3% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
ANI Pharmaceuticals beats Arcus Biosciences on 11 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ANIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ANI Pharmaceuticals (NASDAQ:ANIP) vs. Its Competitors
ANI Pharmaceuticals Competitors List
